The New England journal of medicine, 2019-08, Vol.381 (5), p.432-443
- Shanafelt, Tait D
- Wang, Xin V
- Kay, Neil E
- Hanson, Curtis A
- O’Brien, Susan
- Barrientos, Jacqueline
- Jelinek, Diane F
- Braggio, Esteban
- Leis, Jose F
- Zhang, Cong C
- Coutre, Steven E
- Barr, Paul M
- Cashen, Amanda F
- Mato, Anthony R
- Singh, Avina K
- Mullane, Michael P
- Little, Richard F
- Erba, Harry
- Stone, Richard M
- Litzow, Mark
- Tallman, Martin
2019
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Shanafelt, Tait D
- Wang, Xin V
- Kay, Neil E
- Hanson, Curtis A
- O’Brien, Susan
- Barrientos, Jacqueline
- Jelinek, Diane F
- Braggio, Esteban
- Leis, Jose F
- Zhang, Cong C
- Coutre, Steven E
- Barr, Paul M
- Cashen, Amanda F
- Mato, Anthony R
- Singh, Avina K
- Mullane, Michael P
- Little, Richard F
- Erba, Harry
- Stone, Richard M
- Litzow, Mark
- Tallman, Martin
- Titel
- Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
- Ist Teil von
- The New England journal of medicine, 2019-08, Vol.381 (5), p.432-443
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2019
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Patients 70 years of age or younger with previously untreated CLL were randomly assigned to receive ibrutinib plus rituximab or chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab. The ibrutinib-based regimen led to prolonged progression-free and overall survival.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1817073Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6908306
- Format
- –
- Schlagworte
- Adenine - analogs & derivatives, Age, Aged, Antineoplastic Combined Chemotherapy Protocols - adverse effects, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Cancer therapies, Chronic lymphocytic leukemia, Collaboration, Cyclophosphamide, Cyclophosphamide - administration & dosage, Cyclophosphamide - adverse effects, Death, Drug dosages, FDA approval, Female, Fludarabine, Humans, Immunotherapy, Inhibitor drugs, Intention to Treat Analysis, Kaplan-Meier Estimate, Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell - mortality, Lymphatic leukemia, Male, Medical research, Middle Aged, Monoclonal antibodies, Mutation, Oncology, Pharmaceuticals, Piperidines, Progression-Free Survival, Pyrazoles - administration & dosage, Pyrazoles - adverse effects, Pyrimidines - administration & dosage, Pyrimidines - adverse effects, R&D, Research & development, Rituximab, Rituximab - administration & dosage, Rituximab - adverse effects, Survival, Targeted cancer therapy, Variable region, Vidarabine - administration & dosage, Vidarabine - adverse effects, Vidarabine - analogs & derivatives